Improving homing in T cell therapy

Cytokine and Growth Factor Reviews

Volumn 36, Issue , 2017, Pages 107-116

  Vignali, Debora ^a   Kallikourdis, Marinos ^a,b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

Author keywords

Adaptive cell therapy; Chemokines; Homing; T cells; Tumor

Indexed keywords

ANTIFIBROTIC AGENT; CCL1 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CXCL1 CHEMOKINE; CXCL16 CHEMOKINE; DEFACTINIB; MONOCYTE CHEMOTACTIC PROTEIN 1; PEMBROLIZUMAB; STROMAL CELL DERIVED FACTOR 1; TUMOR PROTEIN; UNCLASSIFIED DRUG; VS 4718;

ADOPTIVE TRANSFER; BLOOD VESSEL; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ENGINEERING; CELL HOMING; CELL MIGRATION; CELL THERAPY; CHEMOKINESIS; CYTOTOXIC T LYMPHOCYTE; DRUG MECHANISM; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; LYMPHOCYTE FUNCTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY; TUMOR GROWTH; TUMOR HYPOXIA; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL MOTION; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; NEOPLASM; PROCEDURES;

ANIMALS; CELL MOVEMENT; CHEMOKINES; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; MICE; NEOPLASMS; RECEPTORS, CHEMOKINE; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 85021790772     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2017.06.009     Document Type: Short Survey

References (100)

1. Man, Y.G., Mason, J., Harley, R., Kim, Y.H., Zhu, K., Gardner, W.A., Leukocyte-mediated cell dissemination and metastasis: findings from multiple types of human tumors. J. Cell. Biochem. 112 (2011), 1154–1167.
2. DeNardo, D.G., Brennan, D.J., Rexhepaj, E., Ruffell, B., Shiao, S.L., Madden, S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1 (2011), 54–67.
3. Berghuis, D., Santos, S.J., Baelde, H.J., Taminiau, A.H., Egeler, R.M., Schilham, M.W., et al. Pro-inflammatory chemokine–chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J. Pathol. 223 (2011), 347–357.
4. Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 (2005), 2654–2666.
5. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
6. Kalos, M., Levine, B.L., Porter, D.L., Katz, S., Grupp, S.A., Bagg, A., et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med., 2011, 95ra73.
7. Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.C., Validire, P., Trautmann, A., et al. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J. Clin. Invest. 122 (2012), 899–910.
8. Bellone, M., Calcinotto, A., Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front. Oncol., 3, 2013, 231.
9. Nagy, J.A., Chang, S.H., Dvorak, A.M., Dvorak, H.F., Why are tumour blood vessels abnormal and why is it important to know. Br. J. Cancer 100 (2009), 865–869.
10. Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H.H., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 453 (2008), 410–414.
11. Motz, G.T., Santoro, S.P., Wang, L.P., Garrabrant, T., Lastra, R.R., Hagemann, I.S., et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat. Med. 20 (2014), 607–615.
12. Chang, C.H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162 (2015), 1229–1241.
13. Corrado, M., Scorrano, L., Campello, S., Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents. Oncotarget, 7, 2016 46692–4706.
14. Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martin-Perez, R., Serneels, J., et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 24 (2016), 701–715.
15. Anderson, K.G., Stromnes, I.M., Greenberg, P.D., Obstacles posed by the tumor microenvironment to t cell activity: a case for synergistic therapies. Cancer Cell 31 (2017), 311–325.
16. Fridman, W.H., Pages, F., Sautes-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
17. Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., Allavena, P., Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin Oncol. 14 (2017), 399–416.
18. Chow, M.T., Luster, A.D., Chemokines in cancer. Cancer Immunol. Res. 2 (2014), 1125–1131.
19. Garetto, S., Trovato, A.E., Lleo, A., Sala, F., Martini, E., Betz, A.G., et al. Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Immunobiology 220 (2015), 1025–1029.
20. De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45 (2016), 1135–1147.
21. Henze, A.T., Mazzone, M., The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest. 126 (2016), 3672–3679.
22. De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208 (2011), 469–478.
23. Giraldo, N.A., Becht, E., Pages, F., Skliris, G., Verkarre, V., Vano, Y., et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res.:Off. J. Am. Assoc. Cancer Res. 21 (2015), 3031–3040.
24. Rosenberg, S.A., Spiess, P., Lafreniere, R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233 (1986), 1318–1321.
25. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
26. Darcy, P.K., Neeson, P., Yong, C.S., Kershaw, M.H., Manipulating immune cells for adoptive immunotherapy of cancer. Curr. Opin. Immunol. 27 (2014), 46–52.
27. Zhang, E., Xu, H., A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy. J. Hematol. Oncol., 10, 2017, 1.
28. Yang, F., Jin, H., Wang, J., Sun, Q., Yan, C., Wei, F., et al. Adoptive cellular therapy (ACT) for cancer treatment. Adv. Exp. Med. Biol. 909 (2016), 169–239.
29. Park, T.S., Rosenberg, S.A., Morgan, R.A., Treating cancer with genetically engineered T cells. Trends Biotechnol. 29 (2011), 550–557.
30. Klebanoff, C.A., Gattinoni, L., Palmer, D.C., Muranski, P., Ji, Y., Hinrichs, C.S., et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res.:Off. J. Am. Assoc. Cancer Res. 17 (2011), 5343–5352.
31. Goff, S.L., Dudley, M.E., Citrin, D.E., Somerville, R.P., Wunderlich, J.R., Danforth, D.N., et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 34 (2016), 2389–2397.
32. van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 31 (2013), e439–42.
33. Pule, M.A., Savoldo, B., Myers, G.D., Rossig, C., Russell, H.V., Dotti, G., et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14 (2008), 1264–1270.
34. Vicente-Manzanares, M., Sanchez-Madrid, F., Role of the cytoskeleton during leukocyte responses. Nat. Rev. Immunol. 4 (2004), 110–122.
35. Salvucci, O., Bouchard, A., Baccarelli, A., Deschenes, J., Sauter, G., Simon, R., et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res. Treat. 97 (2006), 275–283.
36. Smith, M.C., Luker, K.E., Garbow, J.R., Prior, J.L., Jackson, E., Piwnica-Worms, D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 64 (2004), 8604–8612.
37. Marchesi, F., Monti, P., Leone, B.E., Zerbi, A., Vecchi, A., Piemonti, L., et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 64 (2004), 8420–8427.
38. Kitamura, T., Pollard, J.W., Therapeutic potential of chemokine signal inhibition for metastatic breast cancer. Pharmacol. Res. 100 (2015), 266–270.
39. Martin, D., Galisteo, R., Gutkind, J.S., CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J. Biol. Chem. 284 (2009), 6038–6042.
40. Bonecchi, R., Galliera, E., Borroni, E.M., Corsi, M.M., Locati, M., Mantovani, A., Chemokines and chemokine receptors: an overview. Front. Biosci. 14 (2009), 540–551.
41. Shields, J.D., Fleury, M.E., Yong, C., Tomei, A.A., Randolph, G.J., Swartz, M.A., Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11 (2007), 526–538.
42. Tacke, F., Targeting hepatic macrophages to treat liver diseases. J Hepatol. 66 (2017), 1300–1312.
43. Fridlender, Z.G., Kapoor, V., Buchlis, G., Cheng, G., Sun, J., Wang, L.C., et al. Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am. J. Respir. Cell Mol. Biol. 44 (2011), 230–237.
44. Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66 (2017), 157–167.
45. Moisan, F., Francisco, E.B., Brozovic, A., Duran, G.E., Wang, Y.C., Chaturvedi, S., et al. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers. Mol. Oncol. 8 (2014), 1231–1239.
46. Lefebvre, E., Moyle, G., Reshef, R., Richman, L.P., Thompson, M., Hong, F., et al. Antifibrotic effects of the dual CCR2/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis. PLoS One, 11, 2016, e0158156.
47. Abe, R., Donnelly, S.C., Peng, T., Bucala, R., Metz, C.N., Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166 (2001), 7556–7562.
48. Moore, B.B., Kolodsick, J.E., Thannickal, V.J., Cooke, K., Moore, T.A., Hogaboam, C., et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166 (2005), 675–684.
49. Phillips, R.J., Burdick, M.D., Hong, K., Lutz, M.A., Murray, L.A., Xue, Y.Y., et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114 (2004), 438–446.
50. Quante, M., Tu, S.P., Tomita, H., Gonda, T., Wang, S.S., Takashi, S., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19 (2011), 257–272.
51. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
52. Provenzano, P.P., Inman, D.R., Eliceiri, K.W., Knittel, J.G., Yan, L., Rueden, C.T., et al. Collagen density promotes mammary tumor initiation and progression. BMC Med., 6, 2008, 11.
53. Wyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., Stanley, E.R., et al. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 67 (2007), 2649–2656.
54. Fu, H., Ward, E.J., Marelli-Berg, F.M., Mechanisms of T cell organotropism. Cell. Mol. Life Sci.: CMLS 73 (2016), 3009–3033.
55. Slaney, C.Y., Kershaw, M.H., Darcy, P.K., Trafficking of T cells into tumors. Cancer Res. 74 (2014), 7168–7174.
56. Johnston, B., Butcher, E.C., Chemokines in rapid leukocyte adhesion triggering and migration. Semin. Immunol. 14 (2002), 83–92.
57. Fabbri, M., Bianchi, E., Fumagalli, L., Pardi, R., Regulation of lymphocyte traffic by adhesion molecules. Inflammation Res.: Off. J. Eur. Histamine Res. Soc. [et al.] 48 (1999), 239–246.
58. Mahnke, Y.D., Brodie, T.M., Sallusto, F., Roederer, M., Lugli, E., The who's who of T-cell differentiation: human memory T-cell subsets. Eur. J. Immunol. 43 (2013), 2797–2809.
59. Ohtani, H., Jin, Z., Takegawa, S., Nakayama, T., Yoshie, O., Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J. Pathol. 217 (2009), 21–31.
60. Oldham, K.A., Parsonage, G., Bhatt, R.I., Wallace, D.M., Deshmukh, N., Chaudhri, S., et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur. Urol. 61 (2012), 385–394.
61. Musha, H., Ohtani, H., Mizoi, T., Kinouchi, M., Nakayama, T., Shiiba, K., et al. Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int. J. Cancer 116 (2005), 949–956.
62. Hollenbaugh, J.A., Dutton, R.W., IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J. Immunol. 177 (2006), 3004–3011.
63. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (2009), 3077–3085.
64. Sapoznik, S., Ortenberg, R., Galore-Haskel, G., Kozlovski, S., Levy, D., Avivi, C., et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol. Immunother.: CII 61 (2012), 1833–1847.
65. Coppola, D., Nebozhyn, M., Khalil, F., Dai, H., Yeatman, T., Loboda, A., et al. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179 (2011), 37–45.
66. de Chaisemartin, L., Goc, J., Damotte, D., Validire, P., Magdeleinat, P., Alifano, M., et al. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71 (2011), 6391–6399.
67. Allaoui, R., Bergenfelz, C., Mohlin, S., Hagerling, C., Salari, K., Werb, Z., et al. Cancer-associated fibroblast-secreted CXCL16 attracts monocytes to promote stroma activation in triple-negative breast cancers. Nat. Commun., 7, 2016, 13050.
68. Kershaw, M.H., Wang, G., Westwood, J.A., Pachynski, R.K., Tiffany, H.L., Marincola, F.M., et al. Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum. Gene Ther. 13 (2002), 1971–1980.
69. Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Muhitch, J.B., et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun., 6, 2015, 7458.
70. Barreira da Silva, R., Laird, M.E., Yatim, N., Fiette, L., Ingersoll, M.A., Albert, M.L., Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat. Immunol. 16 (2015), 850–858.
71. Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208 (2011), 1949–1962.
72. Mueller, M.M., Fusenig, N.E., Friends or foes − bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 4 (2004), 839–849.
73. Orimo, A., Weinberg, R.A., Heterogeneity of stromal fibroblasts in tumors. Cancer Biol. Ther. 6 (2007), 618–619.
74. Stuelten, C.H., DaCosta Byfield, S., Arany, P.R., Karpova, T.S., Stetler-Stevenson, W.G., Roberts, A.B., Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J. Cell Sci. 118 (2005), 2143–2153.
75. Kojima, Y., Acar, A., Eaton, E.N., Mellody, K.T., Scheel, C., Ben-Porath, I., et al. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 20009–20014.
76. Friman, T., Gustafsson, R., Stuhr, L.B., Chidiac, J., Heldin, N.E., Reed, R.K., et al. Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin beta3-subunit deficient mice. PLoS One, 7, 2012, e34082.
77. Ozdemir, B.C., Pentcheva-Hoang, T., Carstens, J.L., Zheng, X., Wu, C.C., Simpson, T.R., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25 (2014), 719–734.
78. Kraman, M., Bambrough, P.J., Arnold, J.N., Roberts, E.W., Magiera, L., Jones, J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330 (2010), 827–830.
79. Feig, C., Jones, J.O., Kraman, M., Wells, R.J., Deonarine, A., Chan, D.S., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 20212–20217.
80. Ager, A., Watson, H.A., Wehenkel, S.C., Mohammed, R.N., Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells. Biochem. Soc. Trans. 44 (2016), 377–385.
81. Dieu-Nosjean, M.C., Giraldo, N.A., Kaplon, H., Germain, C., Fridman, W.H., Sautes-Fridman, C., Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol. Rev. 271 (2016), 260–275.
82. Peske, J.D., Thompson, E.D., Gemta, L., Baylis, R.A., Fu, Y.X., Engelhard, V.H., Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun., 6, 2015, 7114.
83. Yoong, K.F., McNab, G., Hubscher, S.G., Adams, D.H., Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160 (1998), 3978–3988.
84. Clark, R.A., Huang, S.J., Murphy, G.F., Mollet, I.G., Hijnen, D., Muthukuru, M., et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205 (2008), 2221–2234.
85. Hellebrekers, D.M., Castermans, K., Vire, E., Dings, R.P., Hoebers, N.T., Mayo, K.H., et al. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 66 (2006), 10770–10777.
86. Peng, W., Ye, Y., Rabinovich, B.A., Liu, C., Lou, Y., Zhang, M., et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 16 (2010), 5458–5468.
87. Craddock, J.A., Lu, A., Bear, A., Pule, M., Brenner, M.K., Rooney, C.M., et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33 (2010), 780–788.
88. Moon, E.K., Carpenito, C., Sun, J., Wang, L.C., Kapoor, V., Predina, J., et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res.:Off. J. Am. Assoc. Cancer Res. 17 (2011), 4719–4730.
89. Siddiqui, I., Erreni, M., van Brakel, M., Debets, R., Allavena, P., Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient. J. Immunother. Cancer, 4, 2016, 21.
90. Garetto, S., Sardi, C., Martini, E., Roselli, G., Morone, D., Angioni, R., et al. Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model. Oncotarget 7 (2016), 43010–43026.
91. Takai, K., Le, A., Weaver, V.M., Werb, Z., Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7 (2016), 82889–82901.
92. Polydorou, C., Mpekris, F., Papageorgis, P., Voutouri, C., Stylianopoulos, T., Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Oncotarget 8 (2017), 24506–24517.
93. Straub, J.M., New, J., Hamilton, C.D., Lominska, C., Shnayder, Y., Thomas, S.M., Radiation-induced fibrosis: mechanisms and implications for therapy. J. Cancer Res. Clin. Oncol. 141 (2015), 1985–1994.
94. Jiang, H., Hegde, S., Knolhoff, B.L., Zhu, Y., Herndon, J.M., Meyer, M.A., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22 (2016), 851–860.
95. Shrimali, R.K., Yu, Z., Theoret, M.R., Chinnasamy, D., Restifo, N.P., Rosenberg, S.A., Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 70 (2010), 6171–6180.
96. Kandalaft, L.E., Powell, D.J. Jr., Chiang, C.L., Tanyi, J., Kim, S., Bosch, M., et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology, 2, 2013, e22664.
97. Buckanovich, R.J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14 (2008), 28–36.
98. Seaman, S., Zhu, Z., Saha, S., Zhang, X.M., Yang, M.Y., Hilton, M.B., et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell 31 (2017), 501–515 (e8).
99. Barbee, M.S., Ogunniyi, A., Horvat, T.Z., Dang, T.O., Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann. Pharmacother. 49 (2015), 907–937.
100. Symeonides, S.N., Anderton, S.M., Serrels, A., FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer. J. Immunother. Cancer, 5, 2017, 17.